-+ 0.00%
-+ 0.00%
-+ 0.00%

Corvus spotlights Phase 1 soquelitinib atopic dermatitis trial data showing drug-free remissions

PUBT·04/21/2026 11:31:47
Listen to the news
Corvus spotlights Phase 1 soquelitinib atopic dermatitis trial data showing drug-free remissions
  • Corvus Pharmaceuticals scheduled May 14 investor and analyst meeting to highlight Phase 1 soquelitinib study findings in moderate-to-severe atopic dermatitis.
  • Trial results will be presented in future oral sessions at Society for Investigative Dermatology annual meeting in Chicago on May 14 and May 16.
  • Company pointed to new immunologic and biomarker analyses that support drug’s mechanism of action.
  • Corvus also flagged evidence suggesting soquelitinib can drive prolonged drug-free remissions, a potential differentiator for future development and partnering interest.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corvus Pharmaceuticals Inc. published the original content used to generate this news brief on April 21, 2026, and is solely responsible for the information contained therein.